U.S. Markets closed
  • S&P 500

    4,027.81
    +56.54 (+1.42%)
     
  • Dow 30

    32,717.60
    +323.35 (+1.00%)
     
  • Nasdaq

    11,926.24
    +210.16 (+1.79%)
     
  • Russell 2000

    1,771.60
    +18.97 (+1.08%)
     
  • Crude Oil

    72.86
    -0.11 (-0.15%)
     
  • Gold

    1,964.00
    -2.90 (-0.15%)
     
  • Silver

    23.43
    -0.04 (-0.15%)
     
  • EUR/USD

    1.0847
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    3.5660
    +0.0020 (+0.06%)
     
  • Vix

    19.12
    -0.85 (-4.26%)
     
  • GBP/USD

    1.2313
    +0.0001 (+0.0074%)
     
  • USD/JPY

    132.5960
    -0.1490 (-0.1122%)
     
  • BTC-USD

    28,393.49
    +1,108.72 (+4.06%)
     
  • CMC Crypto 200

    618.50
    +17.53 (+2.92%)
     
  • FTSE 100

    7,564.27
    +80.02 (+1.07%)
     
  • Nikkei 225

    27,883.78
    +365.53 (+1.33%)
     

Conformis Shares Jump On Personalized Orthopedic Implants Contract

  • Conformis Inc (NASDAQ: CFMS) entered into a multi-year agreement with Vizient Inc to offer personalized orthopedic implants to Vizient's membership of healthcare facilities.

  • The agreement gives increased access to the entire Conformis knee and hip portfolio to Vizient's membership base, which comprises academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute health care providers.

  • The offering includes:

    • Identity Imprint, a personalized knee replacement system.

    • Image-to-Implant Platinum Services Program, a patient-elected deluxe upgrade option to obtain a fully personalized knee replacement implant.

    • Cordera Match Hip System, a personalized primary hip replacement solution.

  • Researchers at the University of Washington in Seattle found that fully personalized total knee arthroplasty is cost-effective compared to a standard, off-the-shelf implant.

  • Ongoing research suggests that fully personalized implants further reduce total costs to the healthcare system because patients recover more quickly and are less likely to require follow-up corrective (revision) surgeries.

  • Price Action: CFMS shares are up 4.31% at $0.27 during the premarket session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.